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Hypothesis that vascular system feeding cancer 
cells could �e targeted �y anticancer therapy was 
firstly stated in ����th �y Fоlkman�� who showed that 
there is no sufficiently developed �lood vessels system 
in dormant metastatic nodes [�]. 
Now it is postulated that growth and progression of 
solid tumor greatly depends on its angiogenesis. The 
new strategy for treatment of cancer patients �ased on 
inhi�ition of �lood vessels growth has �een developed. 
�ifferent anticancer drugs possessing antiangiogenic 
properties are currently at different stages of clinical 
trials. Although the fast development of molecular 
�iology and chemistry allowed to generate de novo 
synthetic drugs�� plants are still traditionally used as a 
sources of �iologically active su�stances: a�out �5% 
of all modern anticancer drugs were o�tained directly 
or indirectly from natural products. Recently a num-
�er of studies are focused on diterpenoid alkaloids�� 
some of which showed high anticancer activity and 
significant antiangiogenic effects [��6]. Aсonitine�� 
which �elongs to the group of neurotoxins�� �elongs to 
diterpenoid alkaloids and represents the su�stance of 
plant origin. Anti-inflammatory�� analgetic and in some 
cases antineoplastic effects of Aconitum species are 
known for many years�� especially in the Far East coun-
tries�� where aconitine-containing plants grow [���]. 
Previously we have studied the antineoplastic ef-
ficacy of aconitine containing agent BC� on the model 
of Lewis lung carcinoma �LLC�� and its cis-diammine-
dichloroplatinum �cis-��P��-resistant variant LLC/R� 
[��]. It was shown that LLC and LLC/R� forms have dif-
ferent metastatic potential and proangiogenic a�ility. 
We found that parental LLC cells were highly metastatic 
and weakly proangiogenic�� however its LLC/R� coun-
terpart is characterized �y weak metastatic activity and 
rather high proangiogenic a�ility [��]. Moreover�� LLC 
is resistant to BC� action�� while for LLC/R� significant 
inhi�ition of tumor growth and metastasis upon met-
ronomic administration of BC� at non-cytotoxic doses 
was o�served. Such difference in anticancer activity 
of BC� could �e explained �y possi�le antiangiogenic 
mechanism of its anticancer action. To test this hy-
pothesis the comparative study of anticancer activity 
of BC� for tumors with angiogenesis dependent and 
independent growth has �een carried out. 
The solid and ascite forms of Ehrlich’s carcinoma 
were used as models of tumors with angiogenesis 
dependent and independent growth.
Investigations were carried out on white in�red fe-
male mice weighting ����� g ���.5 months old�� �red 
�y vivarium of R.E. Kavetsky Institute of Experimental 
Pathology�� Oncology and Radio�iology of National 
Academy of Sciences of Ukraine �Kyiv�� Ukraine��. All 
investigations with animals were approved �y the Re-
gional Animal Ethics Committee. 
Cells of Ehrlich’s carcinoma ���6 cells/mice�� were 
either inoculated su�cutaneously into the leg at the 
volume of �.� ml of physiologic solution �for solid 
form���� or injected intraperitoneally at the volume of 
�.5 ml of physiologic solution �for ascite form��. Next 
day mice were divided according to their weight and 
separated into control and experimental groups 
��� mice per group��.
BC� is a new her�al preparation produced on the 
�ase of extract of Aconitum species [��]. The calculati-
on of BC� dose was �ased on the content of aconitine 
as a main active su�stance. For anticancer therapy 
BC� was dissolved in water ex tempore. For mice 
with ascite and solid tumors�� �eginning on the �nd day 
after tumor cell inoculation�� the drug was administered 
per os ��.4 ml aconitine animal�� on 5 consecutive days 
followed �y � drug-free-days �5-days-per-week sche-
dule�� for � weeks. The total dose of BC� per animal was 
�8 µg. The animals from control group received �.4 ml 
water per os. Mice were under daily o�servation�� and 
their weight was registered triply per week.
In the case of solid form of Ehrlich’s carcinoma 
tumor size was recorded �with caliper�� triply per week 
for �� days. Anticancer activity of BC� against solid 
form of Ehrlich’s carcinoma was characterized �y 
growth inhi�ition index GI �at the end of therapy and 
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in a week after its completion���� which was calculated 
using formula:
�Vk � V��GI = ———— · ���%
Vk
where V�� Vk — average tumor volume for experi-
mental and control groups correspondingly. 
The average life span �ALS�� for animals �earing 
ascite tumors was determined for control and experi-
mental groups. The weight of animals was monitored 
during the study�� and was used as an additional crite-
rion of BC� anticancer activity.
Statistical analysis of the data was done using 
descriptive statistic and parametric t-criteria in the 
framework of Microsoft Excel and Microcal Origin.
Kinetic analysis of survival of mice �earing ascite 
form of Ehrlich’s carcinoma showed that BC� therapy 
didn’t result in the increase of ALS �Fig. ���: ALS of mice 
from experimental group was ��.� ± �.� days and did 
not differ statistically from that of mice from control 
group ���.5 ± �.� days��. However�� it can �e noted that 
a minor tendency towards increase of ALS for mice 
with аscite form of Ehrlich’s carcinoma treated with 
BC� was o�served. 
Fig. 1. Survival of mice �earing ascite form of Ehrlich’s carci-
noma �control and experimental groups��
The low/undetecta�le level of BC� anticancer ac-
tivity in the case of ascite form of Ehrlich’s carcinoma 
was confirmed also �y analysis of animals weight: �y 
this parameter no significant difference �etween two 
groups was registered �Fig. ���. 
Fig. 2. �ynamics of weight changes in mice with ascite form of 
Ehrlich’s carcinoma �control and experimental groups��
Completely different anticancer activity of BC� 
was o�served in the case of solid form of Ehrlich’s 
carcinoma. Growth kinetic analysis showed that ad-
ministration of BC� resulted in su�stantial retardation 
of tumor growth �Fig. ���. Interestingly�� there were no 
differences in the tumor volume in mice in control and 
experimental group till �5th day. However after that the 
significant tumor growth inhi�ition was o�served in 
mice in experimental group�� while the tumors in control 
mice were growing with the constant rate. Moreover�� 
after �5th day the growth inhi�ition index constantly 
increased reaching �8.4% at the end of BC� therapy 
��8 days after cancer cell inoculation�� and ��.�% — 
in a week after therapy completion �Ta�le��. 
Fig. 3. Growth kinetics of solid form of Ehrlich’s carcinoma dur-
ing therapy with BC�. *p < �.�5.
Table. Growth inhibition index (%) of solid form of Ehrlich’s carcinoma caused 
by BC1 therapy 
Days after cancer cell inoculation Growth inhibition index (%)
18 38.4
26 77.3
Results of our investigations revealed�� that BC� 
has marked anticancer activity in the case of solid 
form of Ehrlich’s carcinoma. At the same time ascite 
form of Ehrlich’s carcinoma was not sensitive to BC� 
therapy. Such difference in BC� anticancer activity 
cannot �e explained �y direct effect of this agent on 
cancer cells and�� most likely�� is associated with the dif-
ferences in angiogenesis of these two forms Ehrlich’s 
carcinoma. In contrast to ascite tumor the growth of 
solid form of Ehrlich’s carcinoma is an angiogenesis 
dependent process. Thus�� significant anticancer effi-
cacy of BC� for tumors with angiogenesis dependent 
growth confirmed our hypothesis a�out the antiangio-
genic mechanism of BC� anticancer action.
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Сравнительный анализ противоопухолевой 
активноСти аконитинСодержащего агента BC1 
по отношению к аСцитной и Солидной формам 
карциномы Эрлиха
Цель: изучить противоопухолевую активность аконитинсодержащего агента ВС1 in vivo. Методы: асцитную и солидную формы 
карциномы Эрлиха перевивали белым беспородным мышам внутрибрюшинно и подкожно соответственно. Противоопухолевую 
активность ВС1 оценивали по показателям ингибирования роста опухоли и средней продолжительности жизни животных. 
Результаты: ВС1 не оказывал противоопухолевого действия в отношении  асцитной формы карциномы Эрлиха, но был активен 
против солидной формы, приводя к 77,3% ингибированию роста опухоли (p < 0,05). Выводы: ВС1 оказывает выраженное 
противоопухолевое действие в отношении злокачественных новообразований с ангиогенеззависимым ростом. 
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